Proactive Investors - Run By Investors For Investors

Namaste Technologies signs deal with Airo Brands to merge cannabis and vaporizers

The cannabis company will sell the pre-filled cartridges through e-commerce platform Cannmart
Man using a vaporizer
Namaste Technologies offers vaporizers, CBD products, glassware and other cannabis-related accessories

Ahead of the upcoming legalization in Canada this fall, cannabis companies are looking for a variety of delivery methods to suit the growing customer base.

Namaste Technologies Inc (TSX-V:N, OTCMKTS:NXTFF) has signed an agreement with Airo Brands Inc to merge its cannabis with Airo’s pre-filled vaporizer cartridge brand.

READ: Namaste Technologies inks deal with Kief Cannabis for artisan-crafted cannabis

In May, the cannabis company acquired a majority share of Infinte Labz Inc, a facility designed to produce cannabis oil.

The lab will provide the cannabis oil for the pre-filled cartridges and Namaste will bring the finished product to the online medical and recreational markets through its subsidiary Cannmart, an e-commerce cannabis platform.

“As we look forward to upcoming legalization and in anticipation of our sales license, we are more focused now than ever before on securing cannabis supply agreements and strategic partnerships with well-known brands like Airo Brands, and in offering value to our partners and our patients,” said CEO Sean Dollinger in the company’s press release.

The Vancouver-based company recently signed a wholesale supply agreement with Kief Cannabis Company Ltd, a producer of small-batch, artisan-crafted cannabis.

Namaste's product offerings include vaporizers, CBD products, glassware and other cannabis-related accessories. The company will sell its own medical cannabis upon Health Canada’s approval.

Shares of the company fell around 2% to US$2.70 in Thursday morning trading.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full N profile View Profile

Namaste Technologies Inc Timeline

Related Articles

Cancer cells
February 06 2019
In October 2018, Maxcyte saw the first patient dosed in an initial phase I trial using its lead MCY-M11 therapy, tracking a total of 15 women with relapsed or hard-to-treat forms of cancer
Collagen testing
August 17 2018
Since reporting its full-year results on July 10, the AIM-listed shares have rallied over 38% in the past month to 3.65p currently, taking year-to-date gains to a third
November 23 2018
The Australian regenerative medicine company is developing a portfolio of innovative cellular therapies targeting significant unmet medical needs with a licence-driven strategy.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use